Company: ENTXW
Filing Date: 2025-05-30
Form Type: S-3
Source: 0001178913-25-002025
Chunk: 50

Company: Entera Bio Ltd.
Filing Date: 2025-05-30
Form: S-3
Chunk 50
---
 meeting, unless such day shall fall on a statutory holiday (either in Israel or in the United States), in which case the meeting will be adjourned to the first business day afterwards. If at such adjourned meeting a quorum as specified above is not present within half an hour from the time designated for holding the meeting, subject to certain exceptions, any two shareholders present in person or by proxy shall constitute a quorum. Preemptive Rights Pursuant to our Articles of Association, no preemptive rights are attached to our ordinary shares. Restrictions on Non-Residents of Israel The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our Articles or the laws of Israel, except for ownership by nationals of some countries that are, or have been, in a state of war with Israel. Preferred Shares Currently there are no preferred shares authorized under the terms of our Articles. No preferred shares are outstanding. Transfer Agent and Registrar The transfer agent and registrar for the ordinary shares is Equiniti Trust Company, LLC. S-14 PLAN OF DISTRIBUTION We have entered into a Sales Agreement with Leerink Partners under which we may issue and sell up to 30,000,000 of our ordinary shares from time to time through or to Leerink Partners acting as our sales agent or principal. Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, Leerink Partners may sell our ordinary shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 promulgated under the Securities Act. We may instruct Leerink Partners not to sell ordinary shares if the sales cannot be effected at or above the price designated by us from time to time. We or Leerink Partners may suspend the offering of ordinary shares upon notice and subject to other conditions. We will pay Leerink Partners commissions, in cash, for its services in acting as agent in the sale of our ordinary shares. Leerink Partners will be entitled to compensation at a fixed commission rate equal to up to 3.0% of the gross sales price per share sold pursuant to the Sales Agreement. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We have also agreed to reimburse Leerink Partners for certain specified expenses, including the fees and disbursements of its legal counsel, in an amount not to exceed $75,000